A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517204-11-00

Acronym

FFCD 1709 - SIRTCI

Enrollment

Registered

2024-08-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

Brief summary

the main objective of this study is to evaluate the progression-free survival at 9 months (accoridng to RECIST 1.1) according to the investigator

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGOXALIPLATINE HOSPIRA 5 mg/ml

DRUGsolution à diluer pour perfusion

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGCAPECITABINE VIATRIS 500 mg

DRUGcomprimé pelliculé

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the main objective of this study is to evaluate the progression-free survival at 9 months (accoridng to RECIST 1.1) according to the investigator	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026